Frazier Life Sciences — 2020 Investments
5 investments dated 2020 · listed companies and verified rows first · show all
BiotechSouth San Francisco, US
Tracy Saxton(Director)Grant E Pickering(Executive Officer, Director, Promoter)Jeff Fairman(Executive Officer)Ashish Khanna(Executive Officer)William Newell(Director)Patrick Enright(Director)
Board seatPatrick Heron· per SEC Form D · $110M raise · filed Apr 2020
Erasca is a clinical-stage oncology company developing therapies targeting RAS- and MAPK pathway-driven cancers using a modality-agnostic approach including small molecules, large molecules, and protein degraders.
BiotechDeep TechDigital HealthMedical DevicesSan Diego, US
Pratik S. Multani, M.D.(Director)Valerie Harding-Start(Director)Jonathan E. Lim, M.D.(President and Executive Chairman)Gary Yeung, CFA(Chief Business Officer)Alexander W. Casdin(Director)James A. Bristol, Ph.D.(Director)
HealthtechSan Carlos, US
Alan Sachs(Director)Laura G. Eichorn(Executive Officer)Dennis Henner(Director)Hugh Y. Rienhoff(Executive Officer, Director)
Board seatPatrick HeronPatrick Heron· per SEC Form D · $80M raise · filed Nov 2020
Iterum Therapeutics develops anti-infective compounds to treat infections caused by multi-drug resistant pathogens.
BiotechDigital HealthHealthtechMedical DevicesDublin, US
Brenton K. Ahrens(Director)Michael W. Dunne(Executive Officer, Promoter)Ronald M. Hunt(Director)Mark Chin(Director)Corey N. Fishman(Executive Officer, Director, Promoter)Robert Hopfner(Director)
Board seatPatrick J. Heron· per SEC Form D · $2.8M raise · filed Jul 2020
BiotechHamilton
Brenton K. Ahrens(Director)James I. Healy(Director)Mark Chin(Director)Patrick J. Heron(Director)Ronald M. Hunt(Director)Shahzad Malik(Director)
Board seatPatrick Heron· per SEC Form D · $51.6M raise · filed Jan 2020
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.